Peyronie's disease and the first user experience of Peyroflex®
https://doi.org/10.21886/2308-6424-2021-9-2-150-156
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
The article deals with the current issues of the etiology, pathogenesis and clinical course of Peyronie's disease. The diagnostic possibilities of using ultrasound sonography are demonstrated. The international data on known treatment options for Peyronie's disease are reviewed. The author describes his own user experience of the Peyroflex® at an early stage of the disease and gives a preliminary assessment of its effectiveness.
About the Authors
G. V. Shirin
«Medsi» Corporate Group
Russian Federation
Competing Interests:
Russian Federation
Gennadiy V. Shirin — M.D.; Head, Urology Division, «Medsi» Corporate Group.
123056, Moscow, 3a Gruzinsky ln.
Tel.: +7 (903) 139-50-27
Competing Interests:
The authors declare no conflicts of interest.
N. A. Fedorova
«AmirMed» Ltd.
Russian Federation
Competing Interests:
Russian Federation
Nataliya A. Fedorova — M.D., Cand.Sc. (M); Ultrasound Diagnostics Physician, «AmirMed» Ltd.
143405, Krasnogorsk, Ilyinskoe hwy, bus stop - «Betsema».
Competing Interests:
The authors declare no conflicts of interest.
References
1. LaRochelle JC, Levine LA. A Survey of primary-care physicians and urologists regarding Peyronie's disease. J Sex Med. 2007;4(4 Pt 2):1167-73. https://doi.org/10.1111/j.1743-6109.2007.00537.x
2. Chung PH, Han TM, Rudnik B, Das AK. Peyronie's disease: what do we know and how do we treat it? Can J Urol. 2020;27(S3):11-19. PMID: 32875997.
3. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006;175(6):2115-8; discussion 2118. https://doi.org/10.1016/S0022-5347(06)00270-9
4. Kalokairinou K, Konstantinidis C, Domazou M, Kalogeropoulos T, Kosmidis P, Gekas A. US Imaging in Peyronie's Disease. J Clin Imaging Sci. 2012;2:63. https://doi.org/10.4103/2156-7514.103053
5. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU-Guidelines Male sexual dysfunction. European Association of Urology, 2019.
6. Hauptmann A, Wagenlehner FME, Diemer T. Aktuelle Therapie der Induratio penis plastica (IPP). Urologe. 2018;57:1139-1152. https://doi.org/10.1007/s00120-018-0752-x
7. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, Wespes E; European Association of Urology. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543-52. https://doi.org/10.1016/j.eururo.2012.05.040
8. Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48-57. https://doi.org/10.2174/187152812798889321
9. Lopez JA, Jarow JP. Penile vascular evaluation of men with Peyronie's disease. J Urol. 1993;149(1):53-5. https://doi.org/10.1016/ s0022-5347(17)35997-9
10. Chung E, Yan H, De Young L, Brock GB. Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. BJU Int. 2012;110(8):1201-5. https://doi.org/10.1111/j.1464-410X.2011.10851.x
11. Levine L, Rybak J, Corder C, Farrel MR. Peyronie's disease plaque calcification--prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013;10(12):3121-8. https://doi.org/10.1111/jsm.12334
12. Maso E. B., Zubarev A. R., Zhukov O. B. Ultrasound diagnostics of vasculogenic erectile dysfunction. M.: Medicine; 2003. (In Russ.).
13. Porst H, Burri A; European Society for Sexual Medicine (ESSM) Educational Committee. Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe. J Sex Med. 2019;16(6):901-908. https://doi.org/10.1016/j.jsxm.2019.03.404. Erratum in: J Sex Med. 2019;16(9):1486
14. Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prog. Reprod. Biol. Med. 1983;9:41-45
15. Halal AA, Geavlete P, Ceban E. Pharmacological therapy in patients diagnosed with Peyronie's disease. J Med Life. 2012;5(2):192-5. PMID: 22802890; PMCID: PMC3391879
16. Paulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120-8. https://doi.org/10.1111/j.2047-2927.2012.00007.x
17. Shah P, Green N, Adib R. A multicentre double blind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease. Prog Reprod Biol Med. 1983;9:61-67
18. Weidner W, Hauck EW, Schnitker J; Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-5; discussion 535-6. https://doi.org/10.1016/j.eururo.2004.12.022
19. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88(1):63-7. https://doi.org/10.1046/j.1464-410x.2001.02241.x
20. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 2002;89(9):895-900. https://doi.org/10.1046/j.1464-410x.2002.02738.x
Review
For citations:
Shirin G.V., Fedorova N.A. Peyronie's disease and the first user experience of Peyroflex®. Urology Herald. 2021;9(2):150-156. (In Russ.) https://doi.org/10.21886/2308-6424-2021-9-2-150-156
Views:
43313
ISSN 2308-6424 (Online)
Email this article 
